Femasys is trading at $2.51, down 5.99% as September 15, 2026 trading remains pressured by broad risk aversion.
- No new company-specific negative announcement was identified; Femasys’s investor-relations page lists September 9 as its latest release, concerning the CapexMD partnership.
- Higher Treasury yields, oil above $105, and Federal Reserve uncertainty are weighing on growth-sensitive biotech shares, while XBI is down 2.11%.